No year-by-year proxy breakdown is on file — common for foreign private issuers and recently listed companies, which do not file a US proxy statement.
Names, titles and pay as reported by the company and its SEC filings, via Financial Modeling Prep. Reference only — nothing here is investment advice, and no affiliation with or endorsement by the people listed is implied.
Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter More
Oct 24, 2026https://www.fool.com/investing/2026/10/24/forget-casgevy-crispr-therapeutics-heart-disease-d/sentiment +0.00
Vertex Highlights Kidney Pipeline as Povetacicept Cuts Proteinuria 52% in Phase III
Oct 24, 2026https://www.marketbeat.com/instant-alerts/event-vertex-highlights-kidney-pipeline-as-povetacicept-cuts-proteinuria-52-in-phase-iii-2026-10-23/sentiment +0.80
Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock.
Oct 18, 2026https://www.fool.com/investing/2026/10/18/cathie-wood-more-crispr-therapeutics-stock-biotech/sentiment +0.20
Biotech's Rebound Reality: Surging M&A Deals Meet Deep Retail Skepticism
Oct 12, 2026https://www.etftrends.com/leveraged-inverse-content-hub/biotechs-rebound-reality-surging-ma-deals-meet-retail-skepticism/sentiment +0.50
Which iShares Healthcare ETF Is the Better Buy: Biotech-Focused IBB or Broad IYH?
Oct 11, 2026https://www.fool.com/coverage/etfs/2026/10/11/which-ishares-healthcare-etf-is-the-better-buy-biotech-focused-ibb-or-broad-iyh/sentiment +0.36
Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains?
Oct 6, 2026https://www.zacks.com/stock/news/3000644/novavax-nvax-surges-20-1-is-this-an-indication-of-further-gains?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|daily_price_change_5%-3000644sentiment -0.20
